<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03348423</url>
  </required_header>
  <id_info>
    <org_study_id>REC-17-023</org_study_id>
    <nct_id>NCT03348423</nct_id>
  </id_info>
  <brief_title>Evaluation of DEX-IN During Outpatient Procedures</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Evaluation of the Efficacy and Safety of DEX-IN Following Painful Outpatient Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Recro Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Recro Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the analgesic efficacy of DEX-IN compared
      with placebo and active control (fentanyl), in subjects undergoing painful outpatient and
      office based procedures.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2017</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind, double-dummy</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Pain Intensity</measure>
    <time_frame>Up to 4 Hours</time_frame>
    <description>Evaluation of subject reported pain intensity scores according to the 11-point Numeric Pain Rating Scale (NPRS; 0-10)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>DEX-IN 50 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine Intranasal Spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl 50 µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous Fentanyl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DEX-IN</intervention_name>
    <description>IN Dexmedetomidine + IV placebo</description>
    <arm_group_label>DEX-IN 50 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>IN Placebo + IV Fentanyl</description>
    <arm_group_label>Fentanyl 50 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IN Placebo + IV Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntarily provide written informed consent

          -  Be planned to undergo a selected office-based or outpatient procedure

          -  Be naïve to the planned procedure, i.e. no repeated or revision procedures

          -  Not pregnant or planning to become pregnant, or using appropriate contraceptive
             measures.

        Exclusion Criteria:

          -  Known allergy to any study treatment or excipient

          -  Have another painful physical condition or anxiety related diagnosis that may confound
             study assessments

          -  Evidence of a clinically significant finding on physical examination, laboratory
             assessment, or ECG

          -  Have signs or a history of significant nasal condition that may interfere with
             intranasal drug delivery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stewart McCallum, MD</last_name>
    <phone>484-395-2470</phone>
    <phone_ext>2411</phone_ext>
    <email>smccallum@recropharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Randall Mack</last_name>
    <phone>484-395-2470</phone>
    <phone_ext>2406</phone_ext>
    <email>rmack@recropharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2017</study_first_submitted>
  <study_first_submitted_qc>November 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peri-procedural pain</keyword>
  <keyword>Pain</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Anxiolysis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

